Clinical

Dataset Information

0

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors


ABSTRACT: This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.

DISEASE(S): Tnbc - Triple-negative Breast Cancer,Rcc,Solid Tumor,Crc,Triple Negative Breast Neoplasms,Clear Cell Renal Cell Carcinoma,Colorectal Cancer,Carcinoma, Renal Cell,Ccrcc

PROVIDER: 2299826 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| EGAS00001004930 | EGA
2020-07-23 | GSE154941 | GEO
2013-10-31 | E-MTAB-1353 | biostudies-arrayexpress
2023-04-13 | GSE227947 | GEO
| 9330 | ecrin-mdr-crc
2015-11-09 | E-GEOD-73588 | biostudies-arrayexpress
| PRJNA188497 | ENA
2017-09-02 | GSE86394 | GEO
2016-06-25 | E-GEOD-83718 | biostudies-arrayexpress
2015-09-09 | GSE72795 | GEO